Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer
Mark G. Kris, MD
Published Online: Wednesday, December 12, 2012
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the initial trials studying dacomitinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), in patients with EGFR-mutant lung cancers.
Kris explains that dacomitinib was first studied in hopes that a greater, potentially permanent, tumor shrinkage would occur. A phase II study compared dacomitinib to reversible TKIs such as gefitinib and erlotinib as a first-line treatment for patients with lung cancers. The partial response rate was 74% among patients with EGFR deletions at exons 19 and 21. At one year, progression-free survival (PFS) rate was 77% and median PFS was 17 months.
Dacomitib may be as effective as gefitinib in terms of degree and length of tumor shrinkage, Kris believes.
Panelists describe putting the wealth of recent analyses supporting expanded RAS testing into practice, in order to optimize the utilization of EGFR inhibitors in the treatment of patients with colorectal cancer.
A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.